#BEGIN_DRUGCARD DB08651

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C10H15N2O7PS

# Chemical_IUPAC_Name:
{[(2R,3S,5R)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3-sulfanyloxolan-2-yl]methoxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-15 15:33:38 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
3'-THIO-THYMIDINE-5'-PHOSPHATE

# HET_ID:
TSP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H15N2O7PS/c1-5-3-12(10(14)11-9(5)13)8-2-7(21)6(19-8)4-18-20(15,16)17/h3,6-8,21H,2,4H2,1H3,(H,11,13,14)(H2,15,16,17)/t6-,7+,8-/m1/s1

# InChI_Key:
InChIKey=BORVFKJZAOEGOO-GJMOJQLCSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
8657

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
338.274

# Molecular_Weight_Mono:
338.033758046

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.66

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
1.25e+00 g/l

# Primary_Accession_No:
DB08651

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46937170

# PubChem_Substance_ID:
99445122

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]1(S)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(C)C(=O)NC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:27:06 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X00530

# Drug_Target_1_GenBank_ID_Protein:
41325

# Drug_Target_1_GeneCard_ID:
ecoRVR

# Drug_Target_1_Gene_Name:
ecoRVR

# Drug_Target_1_Gene_Sequence:
>897 bp
ATGAAAGATAAAGTTTTTGTTCCGCCTATAAAATCGCAAGGGATTAAGACTAAACTGGTT
CCGTGCATAAAGAGAATTGTTCCTAAAAACTTTAATGGGGTATGGGTCGAGCCGTTTATG
GGGACTGGAGTTGTTGCCTTTAACGTTGCTCCTAAAGATGCATTATTATGTGATACAAAC
CCTCATTTGATTTCTTTTTATAATGCATTGAAAAATAAAGATATAACAGGGGATCTTGTT
AAGGATTTTTTATATCGTGAAGGTGAAAAACTCTTATTAAGTAATGGTGAGTATTATTAT
GAAGTCAGGGAAAGGTTTAATAATTACAAGGAACCGTTAGATTTTTTATTCTTAAATAGG
TCTTGTTTTAATGGTATGATTAGGTTTAATAGTAAAGGAGGGTTTAATGTTCCTTTTTGT
AAAAAACCAAACAGATTTGCACAAGCATATATTACCAAGATTTCGAATCAAGTTGATAGG
ATTTCTGAAATAATATCAAAAGGGAACTATACATTCTTGTGTCAGTCATTTGAAAAAACT
ATTGGCATGGTAAATAGGGATGATGTTGTTTATTGTGATCCTCCATATATTGGTAGGCAT
GTTGATTATTTTAATTCATGGGGAGAGCGTGACGAGCGTTTATTATTTGAAACGTTATCA
TCTTTGAATGCTACATTTATAACGTCTACGTGGCATCATAATGATTATAGGGAAAATAAG
TACGTTCGTGATTTATGGTCATCTTTTAGAATATTGACAAAAGAACATTTTTATCATGTT
GGAGCGTCCGAAAAAAACAGATCCCCGATGGTAGAGGCGCTAATTACAAATATAGCCAAG
GATATTATTGATCACATTGAAAAAAGTAGTGGGGATATTTTGGTAATTGAAGAGTGA

# Drug_Target_1_General_Function:
Involved in DNA binding

# Drug_Target_1_General_References:
10446231	Thomas MP, Brady RL, Halford SE, Sessions RB, Baldwin GS: Structural analysis of a mutational hot-spot in the EcoRV restriction endonuclease: a catalytic role for a main chain carbonyl group. Nucleic Acids Res. 1999 Sep 1;27(17):3438-45.
1647200	Thielking V, Selent U, Kohler E, Wolfes H, Pieper U, Geiger R, Urbanke C, Winkler FK, Pingoud A: Site-directed mutagenesis studies with EcoRV restriction endonuclease to identify regions involved in recognition and catalysis. Biochemistry. 1991 Jul 2;30(26):6416-22.
6328432	Bougueleret L, Schwarzstein M, Tsugita A, Zabeau M: Characterization of the genes coding for the Eco RV restriction and modification system of Escherichia coli. Nucleic Acids Res. 1984 Apr 25;12(8):3659-76.
7819264	Kostrewa D, Winkler FK: Mg2+ binding to the active site of EcoRV endonuclease: a crystallographic study of complexes with substrate and product DNA at 2 A resolution. Biochemistry. 1995 Jan 17;34(2):683-96.
8491171	Winkler FK, Banner DW, Oefner C, Tsernoglou D, Brown RS, Heathman SP, Bryan RK, Martin PD, Petratos K, Wilson KS: The crystal structure of EcoRV endonuclease and of its complexes with cognate and non-cognate DNA fragments. EMBO J. 1993 May;12(5):1781-95.
9367757	Perona JJ, Martin AM: Conformational transitions and structural deformability of EcoRV endonuclease revealed by crystallographic analysis. J Mol Biol. 1997 Oct 17;273(1):207-25.
9545372	Horton NC, Perona JJ: Role of protein-induced bending in the specificity of DNA recognition: crystal structure of EcoRV endonuclease complexed with d(AAAGAT) + d(ATCTT). J Mol Biol. 1998 Apr 10;277(4):779-87.
9705308	Horton NC, Perona JJ: Recognition of flanking DNA sequences by EcoRV endonuclease involves alternative patterns of water-mediated contacts. J Biol Chem. 1998 Aug 21;273(34):21721-9.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6875

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
28650.1

# Drug_Target_1_Name:
Type-2 restriction enzyme EcoRV

# Drug_Target_1_Number_of_Residues:
245

# Drug_Target_1_PDB_ID:
1EON

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF09233	Endonuc-EcoRV

# Drug_Target_1_Protein_Sequence:
>Type-2 restriction enzyme EcoRV
MSLRSDLINALYDENQKYDVCGIISAEGKIYPLGSDTKVLSTIFELFSRPIINKIAEKHG
YIVEEPKQQNHYPDFTLYKPSEPNKKIAIDIKTTYTNKENEKIKFTLGGYTSFIRNNTKN
IVYPFDQYIAHWIIGYVYTRVATRKSSLKTYNINELNEIPKPYKGVKVFLQDKWVIAGDL
AGSGNTTNIGSIHAHYKDFVEGKGIFDSEDEFLDYWRNYERTSQLRNDKYNNISEYRNWI
YRGRK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Recognizes the double-stranded sequence GATATC and cleaves after T-3

# Drug_Target_1_SwissProt_ID:
P04390

# Drug_Target_1_SwissProt_Name:
T2E5_ECOLX

# Drug_Target_1_Synonyms:
Endonuclease EcoRV
R.EcoRV
Type II restriction enzyme EcoRV

# Drug_Target_1_Theoretical_pI:
9.28

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm. Nucleus

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
TOP2B

# Drug_Target_2_GenBank_ID_Gene:
X68060

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
TOP2B

# Drug_Target_2_Gene_Sequence:
>4866 bp
ATGGCCAAGTCGGGTGGCTGCGGCGCGGGAGCCGGCGTGGGCGGCGGCAACGGGGCACTG
ACCTGGGTGAACAATGCTGCAAAAAAAGAAGAGTCAGAAACTGCCAACAAAAATGATTCT
TCAAAGAAGTTGTCTGTTGAGAGAGTGTATCAGAAGAAGACACAACTTGAACACATTCTT
CTTCGTCCTGATACATATATTGGGTCAGTGGAGCCATTGACGCAGTTCATGTGGGTGTAT
GATGAAGATGTAGGAATGAATTGCAGGGAGGTTACCTTTGTGCCAGGTTTATACAAGATC
TTTGATGAAATTTTGGTTAATGCTGCTGACAATAAACAGAGGGATAAGAACATGACTTGT
ATTAAAGTTTCTATTGATCCTGAATCTAACATTATAAGCATTTGGAATAATGGGAAAGGC
ATTCCAGTAGTAGAACACAAGGTAGAGAAAGTTTATGTTCCTGCTTTAATTTTTGGACAG
CTTTTAACATCCAGTAACTATGATGATGATGAGAAAAAAGTTACAGGTGGTCGTAATGGT
TATGGTGCAAAACTTTGTAATATTTTCAGTACAAAGTTTACAGTAGAAACAGCTTGCAAA
GAATACAAACACAGTTTTAAGCAGACATGGATGAATAATATGATGAAGACTTCTGAAGCC
AAAATTAAACATTTTGATGGTGAAGATTACACATGCATAACATTCCAACCAGATCTGTCC
AAATTTAAGATGGAAAAACTTGACAAGGATATTGTGGCCCTCATGACTAGAAGGGCATAT
GATTTGGCTGGTTCGTGTAGAGGGGTCAAGGTCATGTTTAATGGAAAGAAATTGCCTGTA
AATGGATTTCGCAGTTATGTAGATCTTTATGTGAAAGACAAATTGGATGAAACTGGGGTG
GCCCTGAAAGTTATTCATGAGCTTGCAAATGAAAGATGGGATGTTTGTCTCACATTGAGT
GAAAAAGGATTCCAGCAAATCAGCTTTGTAAATAGTATTGCAACTACAAAAGGTGGACGG
CACGTGGATTATGTGGTAGATCAAGTTGTTGGTAAACTGATTGAAGTAGTTAAGAAAAAG
AACAAAGCTGGTGTATCAGTGAAACCATTTCAAGTAAAAAACCATATATGGGTTTTTATT
AATTGCCTTATTGAAAATCCAACTTTTGATTCTCAGACTAAGGAAAACATGACTCTGCAG
CCCAAAAGTTTTGGGTCTAAATGCCAGCTGTCAGAAAAATTTTTTAAAGCAGCCTCTAAT
TGTGGCATTGTAGAAAGTATCCTGAACTGGGTGAAATTTAAGGCTCAGACTCAGCTGAAT
AAGAAGTGTTCATCAGTAAAATACAGTAAAATCAAAGGTATTCCCAAACTGGATGATGCT
AATGATGCTGGTGGTAAACATTCCCTGGAGTGTACACTGATATTAACAGAGGGAGACTCT
GCCAAATCACTGGCTGTGTCTGGATTAGGTGTGATTGGACGAGACAGATACGGAGTTTTT
CCACTCAGGGGCAAAATTCTTAATGTACGGGAAGCTTCTCATAAACAGATCATGGAAAAT
GCTGAAATAAATAATATTATTAAAATAGTTGGTCTACAATATAAGAAAAGTTACGATGAT
GCAGAATCTCTGAAAACCTTACGCTATGGAAAGATTATGATTATGACCGATCAGGATCAA
GATGGTTCTCACATAAAAGGCCTGCTTATTAATTTCATCCATCACAATTGGCCATCACTT
TTGAAGCATGGTTTTCTTGAAGAGTTCATTACTCCTATTGTAAAGGCAAGCAAAAATAAG
CAGGAACTTTCCTTCTACAGTATTCCTGAATTTGACGAATGGAAAAAACATATAGAAAAC
CAGAAAGCCTGGAAAATAAAGTACTATAAAGGATTGGGTACTAGTACAGCTAAAGAAGCA
AAGGAATATTTTGCTGATATGGAAAGGCATCGCATCTTGTTTAGATATGCTGGTCCTGAA
GATGATGCTGCCATTACCTTGGCATTTAGTAAGAAGAAGATTGATGACAGAAAAGAATGG
TTAACAAATTTTATGGAAGACCGGAGACAGCGTAGGCTACATGGCTTACCAGAGCAATTT
TTATATGGTACTGCAACAAAGCATTTGACTTATAATGATTTCATCAACAAGGAATTGATT
CTCTTCTCAAACTCAGACAATGAAAGATCTATACCATCTCTTGTTGATGGCTTTAAACCT
GGCCAGCGGAAAGTTTTATTTACCTGTTTCAAGAGGAATGATAAACGTGAAGTAAAAGTT
GCCCAGTTGGCTGGCTCTGTTGCTGAGATGTCGGCTTATCATCATGGAGAACAAGCATTG
ATGATGACTATTGTGAATTTGGCTCAGAACTTTGTGGGAAGTAACAACATTAACTTGCTT
CAGCCTATTGGTCAGTTTGGAACTCGGCTTCATGGTGGCAAAGATGCTGCAAGCCCTCGT
TATATTTTCACAATGTTAAGCACTTTAGCAAGGCTACTTTTTCCTGCTGTGGATGACAAC
CTCCTTAAGTTCCTTTATGATGATAATCAACGTGTAGAGCCTGAGTGGTATATTCCTATA
ATTCCCATGGTTTTAATAAATGGTGCTGAGGGCATTGGTACTGGATGGGCTTGTAAACTA
CCCAACTATGATGCTAGGGAAATTGTGAACAATGTCAGACGAATGCTAGATGGCCTGGAT
CCTCATCCCATGCTTCCAAACTACAAAAACTTTAAAGGCACGATTCAAGAACTTGGTCAA
AACCAGTATGCAGTCAGTGGTGAAATATTTGTAGTGGACAGAAACACAGTAGAAATTACA
GAGCTTCCAGTTAGAACTTGGACACAGGTATATAAAGAACAGGTTTTAGAACCTATGCTA
AATGGAACAGATAAAACACCAGCATTAATTTCTGATTATAAAGAATATCATACTGACACA
ACTGTGAAATTTGTGGTGAAAATGACTGAAGAGAAACTAGCACAAGCAGAAGCTGCTGGA
CTGCATAAAGTTTTTAAACTTCAAACTACTCTTACTTGTAATTCCATGGTACTTTTTGAT
CATATGGGATGTCTGAAGAAATATGAAACTGTGCAAGACATTCTGAAAGAATTCTTTGAT
TTACGATTAAGTTATTACGGTTTACGTAAGGAGTGGCTTGTGGGAATGTTGGGAGCAGAA
TCTACAAAGCTTAACAATCAAGCCCGTTTCATTTTAGAGAAGATACAAGGGAAAATTACT
ATAGAGAATAGGTCAAAGAAAGATTTGATTCAAATGTTAGTCCAGAGAGGTTATGAATCT
GACCCAGTGAAAGCCTGGAAAGAAGCACAAGAAAAGGCAGCAGAAGAGGATGAAACACAA
AACCAGCATGATGATAGTTCCTCCGATTCAGGAACTCCTTCAGGCCCAGATTTTAATTAT
ATTTTAAATATGTCTCTGTGGTCTCTTACTAAAGAAAAAGTTGAAGAACTGATTAAACAG
AGAGATGCAAAAGGGCGAGAGGTCAATGATCTTAAAAGAAAATCTCCTTCAGATCTTTGG
AAAGAGGATTTAGCGGCATTTGTTGAAGAACTGGATAAAGTGGAATCTCAAGAACGAGAA
GATGTTCTGGCTGGAATGTCTGGAAAAGCAATTAAAGGTAAAGTTGGCAAACCTAAGGTG
AAGAAACTCCAGTTGGAAGAGACAATGCCCTCACCTTATGGCAGAAGAATAATTCCTGAA
ATTACAGCTATGAAGGCAGATGCCAGCAAAAAGTTGCTGAAGAAGAAGAAGGGTGATCTT
GATACTGCAGCAGTAAAAGTGGAATTTGATGAAGAATTCAGTGGAGCACCAGTAGAAGGT
GCAGGAGAAGAGGCATTGACTCCATCAGTTCCTATAAATAAAGGTCCCAAACCTAAGAGG
GAGAAGAAGGAGCCTGGTACCAGAGTGAGAAAAACACCTACATCATCTGGTAAACCTAGT
GCAAAGAAAGTGAAGAAACGGAATCCTTGGTCAGATGATGAATCCAAGTCAGAAAGTGAT
TTGGAAGAAACAGAACCTGTGGTTATTCCAAGAGATTCTTTGCTTAGGAGAGCAGCAGCC
GAAAGACCTAAATACACATTTGATTTCTCAGAAGAAGAGGATGATGATGCTGATGATGAT
GATGATGACAATAATGATTTAGAGGAATTGAAAGTTAAAGCATCTCCCATAACAAATGAT
GGGGAAGATGAATTTGTTCCTTCAGATGGGTTAGATAAAGATGAATATACATTTTCACCA
GGCAAATCAAAAGCCACTCCAGAAAAATCTTTGCATGACAAAAAAAGTCAGGATTTTGGA
AATCTCTTCTCATTTCCTTCATATTCTCAGAAGTCAGAAGATGATTCAGCTAAATTTGAC
AGTAATGAAGAAGATTCTGCTTCTGTTTTTTCACCATCATTTGGTCTGAAACAGACAGAT
AAAGTTCCAAGTAAAACGGTAGCTGCTAAAAAGGGAAAACCGTCTTCAGATACAGTCCCT
AAGCCCAAGAGAGCCCCAAAACAGAAGAAAGTAGTAGAGGCTGTAAACTCTGACTCGGAT
TCAGAATTTGGCATTCCAAAGAAGACTACAACACCAAAAGGTAAAGGCCGAGGGGCAAAG
AAAAGGAAAGCATCTGGCTCTGAAAATGAAGGCGATTATAACCCTGGCAGGAAAACATCC
AAAACAACAAGCAAGAAACCGAAGAAGACATCTTTTGATCAGGATTCAGATGTGGACATC
TTCCCCTCAGACTTCCCTACTGAGCCACCTTCTCTGCCACGAACCGGTCGGGCTAGGAAA
GAAGTAAAATATTTTACAGAGTCTGATGAAGAAGAAGATGATGTTGATTTTGCAATGTTT
AATTAA

# Drug_Target_2_General_Function:
Involved in ATP binding

# Drug_Target_2_General_References:
10095062	Sng JH, Heaton VJ, Bell M, Maini P, Austin CA, Fisher LM: Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication. Biochim Biophys Acta. 1999 Mar 19;1444(3):395-406.
12821127	Mirski SE, Bielawski JC, Cole SP: Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta. Biochem Biophys Res Commun. 2003 Jul 11;306(4):905-11.
1333583	Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID: Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 1992 Nov 11;20(21):5587-92.
2163884	Austin CA, Fisher LM: Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells. FEBS Lett. 1990 Jun 18;266(1-2):115-7.
2556712	Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5.
8383537	Austin CA, Sng JH, Patel S, Fisher LM: Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1993 Mar 20;1172(3):283-91.
8396237	Davies SL, Jenkins JR, Hickson ID: Human cells express two differentially spliced forms of topoisomerase II beta mRNA. Nucleic Acids Res. 1993 Aug 11;21(16):3719-23.

# Drug_Target_2_HGNC_ID:
HGNC:11990

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4192

# Drug_Target_2_Locus:
3p24

# Drug_Target_2_Molecular_Weight:
183269

# Drug_Target_2_Name:
DNA topoisomerase 2-beta

# Drug_Target_2_Number_of_Residues:
1626

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00521	DNA_topoisoIV
PF02518	HATPase_c
PF08070	DTHCT

# Drug_Target_2_Protein_Sequence:
>DNA topoisomerase 2-beta
MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQ
LEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRD
KNMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVT
GGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNNMMKTSEAKIKHFDGEDYTCITF
QPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKL
DETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIE
VVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKENMTLQPKSFGSKCQLSEKFF
KAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLIL
TEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYK
KSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVK
ASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFR
YAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFI
NKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHH
GEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFP
AVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRM
LDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQV
LEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNS
MVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKI
QGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSG
PDFNYILNMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVE
SQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKK
KKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTS
SGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDD
DADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKK
SQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPS
SDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNP
GRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDV
DFAMFN

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks

# Drug_Target_2_SwissProt_ID:
Q02880

# Drug_Target_2_SwissProt_Name:
TOP2B_HUMAN

# Drug_Target_2_Synonyms:
DNA topoisomerase II, beta isozyme
EC 5.99.1.3

# Drug_Target_2_Theoretical_pI:
8.16

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB08651
